Assessing the Validity of the Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form in Adults With ADHD

Mick, Eric; Faraone, Stephen V.; Spencer, Thomas; Zhang, Huabin F.; Biederman, Joseph

doi:10.1177/1087054707308468

Cited by 81 publications

(70 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fact that the Q-LES-Q(SF) does not represent a GAD-specific patient-reported measure of QOL is another potential limitation. However, the validity of the Q-LES-Q has been convincingly demonstrated across psychiatric disorders (Endicott et al 1993;Ritsner et al 2005;Rossi et al 2005;Endicott et al 2006;Schechter et al 2007;Mick et al 2008;Revicki et al 2008). As an exploratory secondary data analysis, no method to control for the probability of family-wise type I error due to multiple comparisons planned was incorporated beyond Scheffe's method as mentioned for overall comparisons.…”

Section: Discussionmentioning

confidence: 99%

“…The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), in both the long and short form (Q-LES-Q(SF)), is a widely used instrument for measuring QOL and satisfaction. Originally developed for use in clinical trials and among trial participants with a wide variety of mental and medical diseases or disorders (Endicott et al 1993), it has been shown to offer high internal consistency, validity and reproducibility in non-psychiatric populations and in patients with a range of psychiatric illnesses (Endicott et al 1993;Ritsner et al 2005;Rossi et al 2005;Endicott et al 2006;Schechter et al 2007;Mick et al 2008;Revicki et al 2008). Thus, the Q-LES-Q(SF) is a PRO measure that has the potential to extend and complement clinical efficacy endpoints and demonstrate the impact of alleviating GAD symptoms on patients' everyday functioning.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study

Harnam¹,

Wyrwich²,

Revicki³

et al. 2011

Different Views of Anxiety Disorders

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study

Harnam¹,

Wyrwich²,

Revicki³

et al. 2011

Different Views of Anxiety Disorders

View full text Add to dashboard Cite

“…9,10 Quality-of-life is negatively correlated with symptom severity. 8,11,12 Information on the impact of treatment on the broad range of life impairments, behaviors, and sleep or insomnia in adults with ADHD is limited.…”

mentioning

confidence: 99%

Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder

Goodman

Starr

Wen

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of individualized dosing within the approved dose range for osmotic-release oral system (OROS) methylphenidate hydrochloride in adults with attention-deficit/hyperactivity disorder (ADHD). Methods: A double-blind, 6-week trial was conducted between July 2009 and February 2010 at 35 US sites. Adults with ADHD (DSM-IV diagnostic criteria) and a screening ADHD Investigator Symptom Rating Scale (AISRS) score > 24 were randomly assigned to OROS methylphenidate 18 mg or matching placebo. Treatment dose could be increased at 18 mg increments, up to 72 mg/d, until an optimal dose was achieved. AISRS score changes from baseline to end point (primary outcome) were analyzed using analysis of covariance. Results: At baseline, the intent-to-treat population of 169 OROS methylphenidate and 172 placebo subjects (mean age = 35.8 years) had mean (standard deviation [SD]) AISRS scores of 37.8 (6.94) and 37.0 (7.51), respectively. OROS methylphenidate-treated subjects exhibited a significantly greater mean (SD) AISRS score improvement than placebo subjects (-17.1 [12.44] vs -11.7 [13.30]; P < .001). In general, OROS methylphenidate-treated subjects experienced greater improvements than placebo subjects in secondary measures of symptom frequency, cognitive function, work productivity, and quality-of-life. Little effect of OROS methylphenidate was observed in exploratory sleep assessments. The adverse event pattern was similar to previous reports of stimulants in adults with ADHD. Conclusions: OROS methylphenidate treatment with individualized doses titrated to achieve symptom remission demonstrated greater ADHD symptom reduction than placebo treatment. These data support the overall efficacy of OROS methylphenidate treatment in the management of adults with ADHD and provide new possibilities for additional intervention. Trial Registration: ClinicalTrials.gov identifier: NCT00937040

show abstract

“…La suma de las escalas crea el Q-LES-Q total de satisfacción con la vida. El instrumento tiene una consistencia interna adecuada (0.88) y validez concordante con ajuste social (0.72) (Mick, Faraone, Spencer, Zhang, & Biederman, 2008).…”

Section: Relaciones Entre Funciones Ejecutivas Y Calidad De Vida De Junclassified

Relaciones entre Funciones ejecutivas y calidad de vida de jóvenes con trastorno por déficit de atención con hiperactividad (TDAH).

Casas¹,

Forner

Diago

et al. 2016

Revista INFAD de Psicología

View full text Add to dashboard Cite

RESUMENAntecedentes y objetivos. Pocos estudios han analizado la contribución del funcionamiento ejecutivo (FE) a la calidad de vida (CAV) en sujetos con TDAH. Objetivos del trabajo: (1) Explorar las diferencias entre adultos con y sin TDAH en calidad de vida (2) Comparar la calidad de vida entre adultos TDAH con y sin dificultades en funcionamiento ejecutivo (3) Analizar la influencia de los problemas en Funciones ejecutivasven la calidad de vida de adultos con TDAH. Métodología. 36 jóve-nes con TDAH y 27 sin el trastorno cumplimentaron cuestionarios sobre calidad de vida y funcionamiento ejecutivo Resultados. Se hallaron diferencias estadísticamente significativas entre jóvenes TDAH con y sin deterioro en funcionamiento ejecutivo en áreas de calidad de vida. En particular los problemas en la metacognición se asociaron con una menor percepción de calidad de vida. Conclusiones. La identificación de los factores que influyen en la calidad vida puede ayudar a la aplicación de programas de tratamiento más efectivos.Palabras clave: Calidad de vida. Funciones ejecutivas. Metacognición. TDAH ABSTRACT Introducction. Few studies have addressed the contribution of executive functioning (EF) in the quality of life (QoL) in adults with ADHD. The aims of this work are: (1) to explore the differences between adults with and without ADHD on QoL (2) to compare QoL among adults with and without ADHD difficulties in EF (3) to analyze the influence of EF in QoL of adults with ADHD. Methodology.

show abstract

Assessing the Validity of the Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form in Adults With ADHD

Abstract: These results support the validity of the Q-LES-QSF as a measure of quality of life in adults with ADHD.

Cited by 81 publications

References 14 publications

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study

Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder

Relaciones entre Funciones ejecutivas y calidad de vida de jóvenes con trastorno por déficit de atención con hiperactividad (TDAH).

Contact Info

Product

Resources

About